Arrowhead Pharmaceuticals, Inc. (ARWR) Monday announced positive topline results from Part 2 of a Phase 1/2 study of ARO-C3 in patients with IgA nephropathy (IgAN).
ARO-C3 is designed to reduce hepatocyte production of complement component 3 (C3) as a potential treatment for various complement mediated renal diseases.
In Part 2 of the Phase 1/2 study, adult patients with C3 Glomerulopathy (C3G) and IgA Nephropathy (IgAN) received 3 doses of ARO-C3. Maximum mean reduction in C3 of 89 percent and mean sustained reduction of greater than 87 percent through week 24 in patients treated with ARO-C3 were observed. Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41 was achieved by week 24.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.